Loading stock data…
$1.20-0.08 (-6.25%)
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
Acurx Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.20 with a market capitalization of $7M. Wall Street consensus targets $17.00 (3 analysts), implying a +1316.7% move over the next 12 months. The stock is currently near its 52-week low of $1.20, remaining 42.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.31M↓ | -$1.72M↓ | -$1.62M↑ | -$2.03M↑ | -$2.27M |
| Net Income | -$2.25M↓ | -$1.68M↓ | -$1.58M↑ | -$1.99M↑ | -$2.25M |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the po...